WO1992002532A1 - Reactifs de liaison ameliores a base de non nucleotide pour oligomeres - Google Patents
Reactifs de liaison ameliores a base de non nucleotide pour oligomeres Download PDFInfo
- Publication number
- WO1992002532A1 WO1992002532A1 PCT/US1991/008769 US9108769W WO9202532A1 WO 1992002532 A1 WO1992002532 A1 WO 1992002532A1 US 9108769 W US9108769 W US 9108769W WO 9202532 A1 WO9202532 A1 WO 9202532A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- nucleotide
- reagent according
- skeleton
- monomeric unit
- oligomer
- Prior art date
Links
- 125000003729 nucleotide group Chemical group 0.000 title claims abstract description 263
- 239000002773 nucleotide Substances 0.000 title claims abstract description 245
- 239000003153 chemical reaction reagent Substances 0.000 title claims abstract description 138
- 229920000642 polymer Polymers 0.000 claims abstract description 54
- 238000010168 coupling process Methods 0.000 claims description 81
- 238000005859 coupling reaction Methods 0.000 claims description 80
- 230000008878 coupling Effects 0.000 claims description 79
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims description 36
- 230000002411 adverse Effects 0.000 claims description 34
- 108091034117 Oligonucleotide Proteins 0.000 claims description 30
- YACKEPLHDIMKIO-UHFFFAOYSA-N methylphosphonic acid Chemical compound CP(O)(O)=O YACKEPLHDIMKIO-UHFFFAOYSA-N 0.000 claims description 30
- -1 phosphate diester Chemical class 0.000 claims description 28
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 claims description 28
- 239000003446 ligand Substances 0.000 claims description 27
- 125000000217 alkyl group Chemical group 0.000 claims description 23
- 125000006239 protecting group Chemical group 0.000 claims description 22
- 125000003118 aryl group Chemical group 0.000 claims description 18
- 229910052799 carbon Inorganic materials 0.000 claims description 17
- 229910019142 PO4 Inorganic materials 0.000 claims description 15
- 239000001257 hydrogen Substances 0.000 claims description 15
- 229910052739 hydrogen Inorganic materials 0.000 claims description 15
- 239000010452 phosphate Substances 0.000 claims description 15
- 125000004432 carbon atom Chemical group C* 0.000 claims description 14
- 125000004104 aryloxy group Chemical group 0.000 claims description 13
- 229910052736 halogen Inorganic materials 0.000 claims description 10
- 150000002367 halogens Chemical class 0.000 claims description 10
- 125000004435 hydrogen atom Chemical group [H]* 0.000 claims description 9
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 claims description 8
- 125000005415 substituted alkoxy group Chemical group 0.000 claims description 8
- 125000003545 alkoxy group Chemical group 0.000 claims description 7
- 125000004414 alkyl thio group Chemical group 0.000 claims description 7
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical group [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 claims description 7
- 229910052760 oxygen Inorganic materials 0.000 claims description 7
- 239000001301 oxygen Substances 0.000 claims description 7
- 150000001721 carbon Chemical group 0.000 claims description 6
- 150000002148 esters Chemical class 0.000 claims description 6
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 claims description 5
- NINIDFKCEFEMDL-UHFFFAOYSA-N Sulfur Chemical group [S] NINIDFKCEFEMDL-UHFFFAOYSA-N 0.000 claims description 5
- 125000005110 aryl thio group Chemical group 0.000 claims description 5
- 229910052717 sulfur Inorganic materials 0.000 claims description 5
- 239000011593 sulfur Chemical group 0.000 claims description 5
- 125000001841 imino group Chemical group [H]N=* 0.000 claims description 4
- 230000007935 neutral effect Effects 0.000 claims description 2
- 125000003835 nucleoside group Chemical group 0.000 claims 1
- PTMHPRAIXMAOOB-UHFFFAOYSA-L phosphoramidate Chemical compound NP([O-])([O-])=O PTMHPRAIXMAOOB-UHFFFAOYSA-L 0.000 claims 1
- RYYWUUFWQRZTIU-UHFFFAOYSA-K thiophosphate Chemical compound [O-]P([O-])([O-])=S RYYWUUFWQRZTIU-UHFFFAOYSA-K 0.000 claims 1
- 239000003431 cross linking reagent Substances 0.000 abstract description 6
- 238000010348 incorporation Methods 0.000 abstract description 2
- WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 description 60
- AYFVYJQAPQTCCC-GBXIJSLDSA-N L-threonine Chemical compound C[C@@H](O)[C@H](N)C(O)=O AYFVYJQAPQTCCC-GBXIJSLDSA-N 0.000 description 39
- YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 description 35
- 125000005647 linker group Chemical group 0.000 description 29
- 238000000034 method Methods 0.000 description 23
- 239000004473 Threonine Substances 0.000 description 22
- HEDRZPFGACZZDS-MICDWDOJSA-N Trichloro(2H)methane Chemical compound [2H]C(Cl)(Cl)Cl HEDRZPFGACZZDS-MICDWDOJSA-N 0.000 description 22
- 229960002898 threonine Drugs 0.000 description 22
- 238000005160 1H NMR spectroscopy Methods 0.000 description 21
- IAZDPXIOMUYVGZ-WFGJKAKNSA-N Dimethyl sulfoxide Chemical compound [2H]C([2H])([2H])S(=O)C([2H])([2H])[2H] IAZDPXIOMUYVGZ-WFGJKAKNSA-N 0.000 description 20
- 238000006243 chemical reaction Methods 0.000 description 20
- 239000000178 monomer Substances 0.000 description 20
- 125000003088 (fluoren-9-ylmethoxy)carbonyl group Chemical group 0.000 description 19
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 18
- 239000000243 solution Substances 0.000 description 17
- 238000003786 synthesis reaction Methods 0.000 description 17
- JUJWROOIHBZHMG-UHFFFAOYSA-N Pyridine Chemical compound C1=CC=NC=C1 JUJWROOIHBZHMG-UHFFFAOYSA-N 0.000 description 16
- 230000015572 biosynthetic process Effects 0.000 description 16
- ZCCUUQDIBDJBTK-UHFFFAOYSA-N psoralen Chemical compound C1=C2OC(=O)C=CC2=CC2=C1OC=C2 ZCCUUQDIBDJBTK-UHFFFAOYSA-N 0.000 description 16
- 239000000126 substance Substances 0.000 description 16
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 15
- 239000000047 product Substances 0.000 description 14
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 13
- WYURNTSHIVDZCO-UHFFFAOYSA-N Tetrahydrofuran Chemical compound C1CCOC1 WYURNTSHIVDZCO-UHFFFAOYSA-N 0.000 description 12
- ZMANZCXQSJIPKH-UHFFFAOYSA-N Triethylamine Chemical compound CCN(CC)CC ZMANZCXQSJIPKH-UHFFFAOYSA-N 0.000 description 12
- VLKZOEOYAKHREP-UHFFFAOYSA-N n-Hexane Chemical compound CCCCCC VLKZOEOYAKHREP-UHFFFAOYSA-N 0.000 description 12
- 239000000523 sample Substances 0.000 description 12
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 10
- 239000002904 solvent Substances 0.000 description 10
- ZMXDDKWLCZADIW-UHFFFAOYSA-N N,N-Dimethylformamide Chemical compound CN(C)C=O ZMXDDKWLCZADIW-UHFFFAOYSA-N 0.000 description 9
- 108020004707 nucleic acids Proteins 0.000 description 9
- 102000039446 nucleic acids Human genes 0.000 description 9
- 150000007523 nucleic acids Chemical class 0.000 description 9
- YBJHBAHKTGYVGT-ZKWXMUAHSA-N (+)-Biotin Chemical compound N1C(=O)N[C@@H]2[C@H](CCCCC(=O)O)SC[C@@H]21 YBJHBAHKTGYVGT-ZKWXMUAHSA-N 0.000 description 8
- JGFZNNIVVJXRND-UHFFFAOYSA-N N,N-Diisopropylethylamine (DIPEA) Chemical compound CCN(C(C)C)C(C)C JGFZNNIVVJXRND-UHFFFAOYSA-N 0.000 description 8
- 239000003795 chemical substances by application Substances 0.000 description 8
- 239000000203 mixture Substances 0.000 description 8
- UMJSCPRVCHMLSP-UHFFFAOYSA-N pyridine Natural products COC1=CC=CN=C1 UMJSCPRVCHMLSP-UHFFFAOYSA-N 0.000 description 8
- 239000011541 reaction mixture Substances 0.000 description 8
- VXGRJERITKFWPL-UHFFFAOYSA-N 4',5'-Dihydropsoralen Natural products C1=C2OC(=O)C=CC2=CC2=C1OCC2 VXGRJERITKFWPL-UHFFFAOYSA-N 0.000 description 7
- AYFVYJQAPQTCCC-UHFFFAOYSA-N Threonine Natural products CC(O)C(N)C(O)=O AYFVYJQAPQTCCC-UHFFFAOYSA-N 0.000 description 7
- 230000000903 blocking effect Effects 0.000 description 7
- 230000000295 complement effect Effects 0.000 description 7
- 238000010511 deprotection reaction Methods 0.000 description 7
- 150000005690 diesters Chemical class 0.000 description 7
- 238000002372 labelling Methods 0.000 description 7
- VKIGAWAEXPTIOL-UHFFFAOYSA-N 2-hydroxyhexanenitrile Chemical compound CCCCC(O)C#N VKIGAWAEXPTIOL-UHFFFAOYSA-N 0.000 description 6
- XKRFYHLGVUSROY-UHFFFAOYSA-N Argon Chemical compound [Ar] XKRFYHLGVUSROY-UHFFFAOYSA-N 0.000 description 6
- 230000006820 DNA synthesis Effects 0.000 description 6
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 6
- 239000000872 buffer Substances 0.000 description 6
- 125000002887 hydroxy group Chemical group [H]O* 0.000 description 6
- HWCKGOZZJDHMNC-UHFFFAOYSA-M tetraethylammonium bromide Chemical compound [Br-].CC[N+](CC)(CC)CC HWCKGOZZJDHMNC-UHFFFAOYSA-M 0.000 description 6
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 5
- JLCPHMBAVCMARE-UHFFFAOYSA-N [3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-hydroxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methyl [5-(6-aminopurin-9-yl)-2-(hydroxymethyl)oxolan-3-yl] hydrogen phosphate Polymers Cc1cn(C2CC(OP(O)(=O)OCC3OC(CC3OP(O)(=O)OCC3OC(CC3O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c3nc(N)[nH]c4=O)C(COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3CO)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cc(C)c(=O)[nH]c3=O)n3cc(C)c(=O)[nH]c3=O)n3ccc(N)nc3=O)n3cc(C)c(=O)[nH]c3=O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)O2)c(=O)[nH]c1=O JLCPHMBAVCMARE-UHFFFAOYSA-N 0.000 description 5
- 238000010549 co-Evaporation Methods 0.000 description 5
- 108091033319 polynucleotide Proteins 0.000 description 5
- 239000002157 polynucleotide Substances 0.000 description 5
- 102000040430 polynucleotide Human genes 0.000 description 5
- 238000002360 preparation method Methods 0.000 description 5
- 102000004169 proteins and genes Human genes 0.000 description 5
- 108090000623 proteins and genes Proteins 0.000 description 5
- 238000000746 purification Methods 0.000 description 5
- 239000000741 silica gel Substances 0.000 description 5
- 229910002027 silica gel Inorganic materials 0.000 description 5
- ASJSAQIRZKANQN-CRCLSJGQSA-N 2-deoxy-D-ribose Chemical group OC[C@@H](O)[C@@H](O)CC=O ASJSAQIRZKANQN-CRCLSJGQSA-N 0.000 description 4
- CSNNHWWHGAXBCP-UHFFFAOYSA-L Magnesium sulfate Chemical compound [Mg+2].[O-][S+2]([O-])([O-])[O-] CSNNHWWHGAXBCP-UHFFFAOYSA-L 0.000 description 4
- 229960002684 aminocaproic acid Drugs 0.000 description 4
- 229960002685 biotin Drugs 0.000 description 4
- 235000020958 biotin Nutrition 0.000 description 4
- 239000011616 biotin Substances 0.000 description 4
- 239000002738 chelating agent Substances 0.000 description 4
- 238000003776 cleavage reaction Methods 0.000 description 4
- FUZZWVXGSFPDMH-UHFFFAOYSA-N hexanoic acid Chemical compound CCCCCC(O)=O FUZZWVXGSFPDMH-UHFFFAOYSA-N 0.000 description 4
- 238000004128 high performance liquid chromatography Methods 0.000 description 4
- 238000009396 hybridization Methods 0.000 description 4
- 239000012074 organic phase Substances 0.000 description 4
- 230000007017 scission Effects 0.000 description 4
- 239000007787 solid Substances 0.000 description 4
- 238000003756 stirring Methods 0.000 description 4
- ALSQUSUPDQPCQY-UHFFFAOYSA-N (methoxyamino)phosphonous acid Chemical compound CONP(O)O ALSQUSUPDQPCQY-UHFFFAOYSA-N 0.000 description 3
- OISVCGZHLKNMSJ-UHFFFAOYSA-N 2,6-dimethylpyridine Chemical compound CC1=CC=CC(C)=N1 OISVCGZHLKNMSJ-UHFFFAOYSA-N 0.000 description 3
- NDKDFTQNXLHCGO-UHFFFAOYSA-N 2-(9h-fluoren-9-ylmethoxycarbonylamino)acetic acid Chemical compound C1=CC=C2C(COC(=O)NCC(=O)O)C3=CC=CC=C3C2=C1 NDKDFTQNXLHCGO-UHFFFAOYSA-N 0.000 description 3
- WFDIJRYMOXRFFG-UHFFFAOYSA-N Acetic anhydride Chemical compound CC(=O)OC(C)=O WFDIJRYMOXRFFG-UHFFFAOYSA-N 0.000 description 3
- CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 description 3
- KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 3
- UIIMBOGNXHQVGW-UHFFFAOYSA-M Sodium bicarbonate Chemical compound [Na+].OC([O-])=O UIIMBOGNXHQVGW-UHFFFAOYSA-M 0.000 description 3
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 3
- 239000002253 acid Substances 0.000 description 3
- 230000004913 activation Effects 0.000 description 3
- 229910052786 argon Inorganic materials 0.000 description 3
- 230000008901 benefit Effects 0.000 description 3
- 238000004132 cross linking Methods 0.000 description 3
- 239000003937 drug carrier Substances 0.000 description 3
- 229960003692 gamma aminobutyric acid Drugs 0.000 description 3
- 239000000499 gel Substances 0.000 description 3
- PCHJSUWPFVWCPO-UHFFFAOYSA-N gold Chemical compound [Au] PCHJSUWPFVWCPO-UHFFFAOYSA-N 0.000 description 3
- 230000002779 inactivation Effects 0.000 description 3
- 230000000977 initiatory effect Effects 0.000 description 3
- 239000000138 intercalating agent Substances 0.000 description 3
- TVHCXXXXQNWQLP-DMTCNVIQSA-N methyl (2s,3r)-2-amino-3-hydroxybutanoate Chemical compound COC(=O)[C@@H](N)[C@@H](C)O TVHCXXXXQNWQLP-DMTCNVIQSA-N 0.000 description 3
- 239000008188 pellet Substances 0.000 description 3
- 150000004713 phosphodiesters Chemical group 0.000 description 3
- 108090000765 processed proteins & peptides Proteins 0.000 description 3
- 239000006228 supernatant Substances 0.000 description 3
- 238000001308 synthesis method Methods 0.000 description 3
- YLQBMQCUIZJEEH-UHFFFAOYSA-N tetrahydrofuran Natural products C=1C=COC=1 YLQBMQCUIZJEEH-UHFFFAOYSA-N 0.000 description 3
- UVGHPGOONBRLCX-NJSLBKSFSA-N (2,5-dioxopyrrolidin-1-yl) 6-[5-[(3as,4s,6ar)-2-oxo-1,3,3a,4,6,6a-hexahydrothieno[3,4-d]imidazol-4-yl]pentanoylamino]hexanoate Chemical compound C([C@H]1[C@H]2NC(=O)N[C@H]2CS1)CCCC(=O)NCCCCCC(=O)ON1C(=O)CCC1=O UVGHPGOONBRLCX-NJSLBKSFSA-N 0.000 description 2
- JVSFQJZRHXAUGT-UHFFFAOYSA-N 2,2-dimethylpropanoyl chloride Chemical compound CC(C)(C)C(Cl)=O JVSFQJZRHXAUGT-UHFFFAOYSA-N 0.000 description 2
- JKMHFZQWWAIEOD-UHFFFAOYSA-N 2-[4-(2-hydroxyethyl)piperazin-1-yl]ethanesulfonic acid Chemical compound OCC[NH+]1CCN(CCS([O-])(=O)=O)CC1 JKMHFZQWWAIEOD-UHFFFAOYSA-N 0.000 description 2
- SLXKOJJOQWFEFD-UHFFFAOYSA-N 6-aminohexanoic acid Chemical compound NCCCCCC(O)=O SLXKOJJOQWFEFD-UHFFFAOYSA-N 0.000 description 2
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 2
- VEXZGXHMUGYJMC-UHFFFAOYSA-M Chloride anion Chemical compound [Cl-] VEXZGXHMUGYJMC-UHFFFAOYSA-M 0.000 description 2
- 125000000824 D-ribofuranosyl group Chemical group [H]OC([H])([H])[C@@]1([H])OC([H])(*)[C@]([H])(O[H])[C@]1([H])O[H] 0.000 description 2
- ZHNUHDYFZUAESO-UHFFFAOYSA-N Formamide Chemical compound NC=O ZHNUHDYFZUAESO-UHFFFAOYSA-N 0.000 description 2
- DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Chemical compound NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 description 2
- 239000007995 HEPES buffer Substances 0.000 description 2
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 2
- TWRXJAOTZQYOKJ-UHFFFAOYSA-L Magnesium chloride Chemical compound [Mg+2].[Cl-].[Cl-] TWRXJAOTZQYOKJ-UHFFFAOYSA-L 0.000 description 2
- OAICVXFJPJFONN-UHFFFAOYSA-N Phosphorus Chemical group [P] OAICVXFJPJFONN-UHFFFAOYSA-N 0.000 description 2
- 108010021757 Polynucleotide 5'-Hydroxyl-Kinase Proteins 0.000 description 2
- 102000008422 Polynucleotide 5'-hydroxyl-kinase Human genes 0.000 description 2
- PYMYPHUHKUWMLA-LMVFSUKVSA-N Ribose Natural products OC[C@@H](O)[C@@H](O)[C@@H](O)C=O PYMYPHUHKUWMLA-LMVFSUKVSA-N 0.000 description 2
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 2
- DTQVDTLACAAQTR-UHFFFAOYSA-N Trifluoroacetic acid Chemical compound OC(=O)C(F)(F)F DTQVDTLACAAQTR-UHFFFAOYSA-N 0.000 description 2
- 239000007983 Tris buffer Substances 0.000 description 2
- XSQUKJJJFZCRTK-UHFFFAOYSA-N Urea Chemical compound NC(N)=O XSQUKJJJFZCRTK-UHFFFAOYSA-N 0.000 description 2
- HMFHBZSHGGEWLO-UHFFFAOYSA-N alpha-D-Furanose-Ribose Natural products OCC1OC(O)C(O)C1O HMFHBZSHGGEWLO-UHFFFAOYSA-N 0.000 description 2
- 150000001412 amines Chemical group 0.000 description 2
- 229940024606 amino acid Drugs 0.000 description 2
- 229940124277 aminobutyric acid Drugs 0.000 description 2
- 125000002057 carboxymethyl group Chemical group [H]OC(=O)C([H])([H])[*] 0.000 description 2
- 239000003054 catalyst Substances 0.000 description 2
- 238000005119 centrifugation Methods 0.000 description 2
- 125000001309 chloro group Chemical group Cl* 0.000 description 2
- 238000004587 chromatography analysis Methods 0.000 description 2
- 230000021615 conjugation Effects 0.000 description 2
- 238000001212 derivatisation Methods 0.000 description 2
- JXTHNDFMNIQAHM-UHFFFAOYSA-N dichloroacetic acid Chemical compound OC(=O)C(Cl)Cl JXTHNDFMNIQAHM-UHFFFAOYSA-N 0.000 description 2
- 239000003814 drug Substances 0.000 description 2
- 230000002255 enzymatic effect Effects 0.000 description 2
- 239000000706 filtrate Substances 0.000 description 2
- 125000000524 functional group Chemical group 0.000 description 2
- BTCSSZJGUNDROE-UHFFFAOYSA-N gamma-aminobutyric acid Chemical compound NCCCC(O)=O BTCSSZJGUNDROE-UHFFFAOYSA-N 0.000 description 2
- 239000010931 gold Substances 0.000 description 2
- 229910052737 gold Inorganic materials 0.000 description 2
- 108091008039 hormone receptors Proteins 0.000 description 2
- BHEPBYXIRTUNPN-UHFFFAOYSA-N hydridophosphorus(.) (triplet) Chemical group [PH] BHEPBYXIRTUNPN-UHFFFAOYSA-N 0.000 description 2
- 150000002430 hydrocarbons Chemical group 0.000 description 2
- 229910052943 magnesium sulfate Inorganic materials 0.000 description 2
- 239000012528 membrane Substances 0.000 description 2
- MZDMEAKVGTZHES-UHFFFAOYSA-N methylphosphonamidous acid Chemical compound CP(N)O MZDMEAKVGTZHES-UHFFFAOYSA-N 0.000 description 2
- 230000004048 modification Effects 0.000 description 2
- 238000012986 modification Methods 0.000 description 2
- 230000001293 nucleolytic effect Effects 0.000 description 2
- 239000002777 nucleoside Substances 0.000 description 2
- 150000003833 nucleoside derivatives Chemical class 0.000 description 2
- 229940124276 oligodeoxyribonucleotide Drugs 0.000 description 2
- 125000002743 phosphorus functional group Chemical group 0.000 description 2
- 150000004032 porphyrins Chemical class 0.000 description 2
- 102000004196 processed proteins & peptides Human genes 0.000 description 2
- 230000009467 reduction Effects 0.000 description 2
- 238000004007 reversed phase HPLC Methods 0.000 description 2
- 125000000467 secondary amino group Chemical group [H]N([*:1])[*:2] 0.000 description 2
- 229930000044 secondary metabolite Natural products 0.000 description 2
- ATHGHQPFGPMSJY-UHFFFAOYSA-N spermidine Chemical compound NCCCCNCCCN ATHGHQPFGPMSJY-UHFFFAOYSA-N 0.000 description 2
- 108010051423 streptavidin-agarose Proteins 0.000 description 2
- LENZDBCJOHFCAS-UHFFFAOYSA-N tris Chemical compound OCC(N)(CO)CO LENZDBCJOHFCAS-UHFFFAOYSA-N 0.000 description 2
- 239000003643 water by type Substances 0.000 description 2
- 239000011240 wet gel Substances 0.000 description 2
- MUVQIIBPDFTEKM-IUYQGCFVSA-N (2r,3s)-2-aminobutane-1,3-diol Chemical compound C[C@H](O)[C@H](N)CO MUVQIIBPDFTEKM-IUYQGCFVSA-N 0.000 description 1
- LOSXTWDYAWERDB-UHFFFAOYSA-N 1-[chloro(diphenyl)methyl]-2,3-dimethoxybenzene Chemical compound COC1=CC=CC(C(Cl)(C=2C=CC=CC=2)C=2C=CC=CC=2)=C1OC LOSXTWDYAWERDB-UHFFFAOYSA-N 0.000 description 1
- 150000003923 2,5-pyrrolediones Chemical class 0.000 description 1
- OSBLTNPMIGYQGY-UHFFFAOYSA-N 2-amino-2-(hydroxymethyl)propane-1,3-diol;2-[2-[bis(carboxymethyl)amino]ethyl-(carboxymethyl)amino]acetic acid;boric acid Chemical compound OB(O)O.OCC(N)(CO)CO.OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O OSBLTNPMIGYQGY-UHFFFAOYSA-N 0.000 description 1
- XWKFPIODWVPXLX-UHFFFAOYSA-N 2-methyl-5-methylpyridine Natural products CC1=CC=C(C)N=C1 XWKFPIODWVPXLX-UHFFFAOYSA-N 0.000 description 1
- QWTBDIBOOIAZEF-UHFFFAOYSA-N 3-[chloro-[di(propan-2-yl)amino]phosphanyl]oxypropanenitrile Chemical compound CC(C)N(C(C)C)P(Cl)OCCC#N QWTBDIBOOIAZEF-UHFFFAOYSA-N 0.000 description 1
- ZCYVEMRRCGMTRW-UHFFFAOYSA-N 7553-56-2 Chemical compound [I] ZCYVEMRRCGMTRW-UHFFFAOYSA-N 0.000 description 1
- HBAQYPYDRFILMT-UHFFFAOYSA-N 8-[3-(1-cyclopropylpyrazol-4-yl)-1H-pyrazolo[4,3-d]pyrimidin-5-yl]-3-methyl-3,8-diazabicyclo[3.2.1]octan-2-one Chemical class C1(CC1)N1N=CC(=C1)C1=NNC2=C1N=C(N=C2)N1C2C(N(CC1CC2)C)=O HBAQYPYDRFILMT-UHFFFAOYSA-N 0.000 description 1
- QTBSBXVTEAMEQO-UHFFFAOYSA-M Acetate Chemical compound CC([O-])=O QTBSBXVTEAMEQO-UHFFFAOYSA-M 0.000 description 1
- 229920000936 Agarose Polymers 0.000 description 1
- VHUUQVKOLVNVRT-UHFFFAOYSA-N Ammonium hydroxide Chemical compound [NH4+].[OH-] VHUUQVKOLVNVRT-UHFFFAOYSA-N 0.000 description 1
- BVKZGUZCCUSVTD-UHFFFAOYSA-M Bicarbonate Chemical compound OC([O-])=O BVKZGUZCCUSVTD-UHFFFAOYSA-M 0.000 description 1
- KXDHJXZQYSOELW-UHFFFAOYSA-M Carbamate Chemical compound NC([O-])=O KXDHJXZQYSOELW-UHFFFAOYSA-M 0.000 description 1
- CURLTUGMZLYLDI-UHFFFAOYSA-N Carbon dioxide Chemical compound O=C=O CURLTUGMZLYLDI-UHFFFAOYSA-N 0.000 description 1
- HMFHBZSHGGEWLO-SOOFDHNKSA-N D-ribofuranose Chemical compound OC[C@H]1OC(O)[C@H](O)[C@@H]1O HMFHBZSHGGEWLO-SOOFDHNKSA-N 0.000 description 1
- 108090000790 Enzymes Proteins 0.000 description 1
- 102000004190 Enzymes Human genes 0.000 description 1
- PIICEJLVQHRZGT-UHFFFAOYSA-N Ethylenediamine Chemical compound NCCN PIICEJLVQHRZGT-UHFFFAOYSA-N 0.000 description 1
- 239000004471 Glycine Substances 0.000 description 1
- 229910010084 LiAlH4 Inorganic materials 0.000 description 1
- 238000005481 NMR spectroscopy Methods 0.000 description 1
- 101001068640 Nicotiana tabacum Basic form of pathogenesis-related protein 1 Proteins 0.000 description 1
- 101710163270 Nuclease Proteins 0.000 description 1
- 239000004743 Polypropylene Substances 0.000 description 1
- ZLMJMSJWJFRBEC-UHFFFAOYSA-N Potassium Chemical compound [K] ZLMJMSJWJFRBEC-UHFFFAOYSA-N 0.000 description 1
- 230000006819 RNA synthesis Effects 0.000 description 1
- RYYWUUFWQRZTIU-UHFFFAOYSA-N Thiophosphoric acid Chemical class OP(O)(S)=O RYYWUUFWQRZTIU-UHFFFAOYSA-N 0.000 description 1
- 150000007513 acids Chemical class 0.000 description 1
- 150000001251 acridines Chemical class 0.000 description 1
- 125000002015 acyclic group Chemical group 0.000 description 1
- 125000003158 alcohol group Chemical group 0.000 description 1
- 150000003973 alkyl amines Chemical class 0.000 description 1
- 239000002168 alkylating agent Substances 0.000 description 1
- 150000001413 amino acids Chemical class 0.000 description 1
- 239000000908 ammonium hydroxide Substances 0.000 description 1
- 238000004458 analytical method Methods 0.000 description 1
- 239000012300 argon atmosphere Substances 0.000 description 1
- 150000001502 aryl halides Chemical class 0.000 description 1
- 239000012298 atmosphere Substances 0.000 description 1
- 125000004429 atom Chemical group 0.000 description 1
- 230000004888 barrier function Effects 0.000 description 1
- 238000009835 boiling Methods 0.000 description 1
- 239000005388 borosilicate glass Substances 0.000 description 1
- UDSAIICHUKSCKT-UHFFFAOYSA-N bromophenol blue Chemical compound C1=C(Br)C(O)=C(Br)C=C1C1(C=2C=C(Br)C(O)=C(Br)C=2)C2=CC=CC=C2S(=O)(=O)O1 UDSAIICHUKSCKT-UHFFFAOYSA-N 0.000 description 1
- 239000004202 carbamide Substances 0.000 description 1
- 235000011089 carbon dioxide Nutrition 0.000 description 1
- 230000015556 catabolic process Effects 0.000 description 1
- 238000007385 chemical modification Methods 0.000 description 1
- 125000004122 cyclic group Chemical group 0.000 description 1
- 238000006731 degradation reaction Methods 0.000 description 1
- 239000005547 deoxyribonucleotide Substances 0.000 description 1
- 125000002637 deoxyribonucleotide group Chemical group 0.000 description 1
- 238000013461 design Methods 0.000 description 1
- 229960005215 dichloroacetic acid Drugs 0.000 description 1
- 229940079593 drug Drugs 0.000 description 1
- 230000000694 effects Effects 0.000 description 1
- 238000010828 elution Methods 0.000 description 1
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 description 1
- 238000001704 evaporation Methods 0.000 description 1
- 230000008020 evaporation Effects 0.000 description 1
- 230000029142 excretion Effects 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 238000000605 extraction Methods 0.000 description 1
- 238000001914 filtration Methods 0.000 description 1
- 238000003818 flash chromatography Methods 0.000 description 1
- 230000005021 gait Effects 0.000 description 1
- 125000005179 haloacetyl group Chemical group 0.000 description 1
- 238000010438 heat treatment Methods 0.000 description 1
- FUZZWVXGSFPDMH-UHFFFAOYSA-M hexanoate Chemical compound CCCCCC([O-])=O FUZZWVXGSFPDMH-UHFFFAOYSA-M 0.000 description 1
- 239000005556 hormone Substances 0.000 description 1
- 229940088597 hormone Drugs 0.000 description 1
- AFQIYTIJXGTIEY-UHFFFAOYSA-N hydrogen carbonate;triethylazanium Chemical compound OC(O)=O.CCN(CC)CC AFQIYTIJXGTIEY-UHFFFAOYSA-N 0.000 description 1
- 230000003301 hydrolyzing effect Effects 0.000 description 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-M hydroxide Chemical group [OH-] XLYOFNOQVPJJNP-UHFFFAOYSA-M 0.000 description 1
- TUJKJAMUKRIRHC-UHFFFAOYSA-N hydroxyl Chemical group [OH] TUJKJAMUKRIRHC-UHFFFAOYSA-N 0.000 description 1
- 150000002466 imines Chemical class 0.000 description 1
- 238000003780 insertion Methods 0.000 description 1
- 230000037431 insertion Effects 0.000 description 1
- 229910052740 iodine Inorganic materials 0.000 description 1
- 239000011630 iodine Substances 0.000 description 1
- 150000002540 isothiocyanates Chemical class 0.000 description 1
- 239000012280 lithium aluminium hydride Substances 0.000 description 1
- 229910001629 magnesium chloride Inorganic materials 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 125000000956 methoxy group Chemical group [H]C([H])([H])O* 0.000 description 1
- 125000000325 methylidene group Chemical group [H]C([H])=* 0.000 description 1
- 238000002156 mixing Methods 0.000 description 1
- PSHKMPUSSFXUIA-UHFFFAOYSA-N n,n-dimethylpyridin-2-amine Chemical compound CN(C)C1=CC=CC=N1 PSHKMPUSSFXUIA-UHFFFAOYSA-N 0.000 description 1
- LSMZHPCHKDMYMQ-UHFFFAOYSA-N n-[chloro(methyl)phosphoryl]-n-propan-2-ylpropan-2-amine Chemical compound CC(C)N(C(C)C)P(C)(Cl)=O LSMZHPCHKDMYMQ-UHFFFAOYSA-N 0.000 description 1
- QJGQUHMNIGDVPM-UHFFFAOYSA-N nitrogen group Chemical group [N] QJGQUHMNIGDVPM-UHFFFAOYSA-N 0.000 description 1
- 230000000269 nucleophilic effect Effects 0.000 description 1
- 125000001263 nucleosidyl group Chemical group 0.000 description 1
- 239000002751 oligonucleotide probe Substances 0.000 description 1
- 238000002515 oligonucleotide synthesis Methods 0.000 description 1
- 239000007800 oxidant agent Substances 0.000 description 1
- 239000011236 particulate material Substances 0.000 description 1
- 125000002467 phosphate group Chemical group [H]OP(=O)(O[H])O[*] 0.000 description 1
- ZORAAXQLJQXLOD-UHFFFAOYSA-N phosphonamidous acid Chemical compound NPO ZORAAXQLJQXLOD-UHFFFAOYSA-N 0.000 description 1
- 150000008298 phosphoramidates Chemical class 0.000 description 1
- 150000008300 phosphoramidites Chemical class 0.000 description 1
- 229910052698 phosphorus Inorganic materials 0.000 description 1
- 239000011574 phosphorus Substances 0.000 description 1
- 230000000865 phosphorylative effect Effects 0.000 description 1
- 229920001155 polypropylene Polymers 0.000 description 1
- 239000011148 porous material Substances 0.000 description 1
- 239000011591 potassium Substances 0.000 description 1
- 229910052700 potassium Inorganic materials 0.000 description 1
- 238000001556 precipitation Methods 0.000 description 1
- 150000003141 primary amines Chemical class 0.000 description 1
- 230000009145 protein modification Effects 0.000 description 1
- 230000002797 proteolythic effect Effects 0.000 description 1
- 230000009257 reactivity Effects 0.000 description 1
- 108020003175 receptors Proteins 0.000 description 1
- 102000005962 receptors Human genes 0.000 description 1
- 125000000548 ribosyl group Chemical group C1([C@H](O)[C@H](O)[C@H](O1)CO)* 0.000 description 1
- 108010062513 snake venom phosphodiesterase I Proteins 0.000 description 1
- 150000003385 sodium Chemical class 0.000 description 1
- 239000007974 sodium acetate buffer Substances 0.000 description 1
- 229910000030 sodium bicarbonate Inorganic materials 0.000 description 1
- 235000017557 sodium bicarbonate Nutrition 0.000 description 1
- 239000011780 sodium chloride Substances 0.000 description 1
- 239000001488 sodium phosphate Substances 0.000 description 1
- 229910000162 sodium phosphate Inorganic materials 0.000 description 1
- 238000010532 solid phase synthesis reaction Methods 0.000 description 1
- 239000002195 soluble material Substances 0.000 description 1
- 229940063673 spermidine Drugs 0.000 description 1
- 239000007858 starting material Substances 0.000 description 1
- 229940124597 therapeutic agent Drugs 0.000 description 1
- 125000004044 trifluoroacetyl group Chemical group FC(C(=O)*)(F)F 0.000 description 1
- RYFMWSXOAZQYPI-UHFFFAOYSA-K trisodium phosphate Chemical compound [Na+].[Na+].[Na+].[O-]P([O-])([O-])=O RYFMWSXOAZQYPI-UHFFFAOYSA-K 0.000 description 1
- 125000002221 trityl group Chemical group [H]C1=C([H])C([H])=C([H])C([H])=C1C([*])(C1=C(C(=C(C(=C1[H])[H])[H])[H])[H])C1=C([H])C([H])=C([H])C([H])=C1[H] 0.000 description 1
- 238000005866 tritylation reaction Methods 0.000 description 1
- 238000003260 vortexing Methods 0.000 description 1
- 238000005406 washing Methods 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
- C07H21/00—Compounds containing two or more mononucleotide units having separate phosphate or polyphosphate groups linked by saccharide radicals of nucleoside groups, e.g. nucleic acids
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C271/00—Derivatives of carbamic acids, i.e. compounds containing any of the groups, the nitrogen atom not being part of nitro or nitroso groups
- C07C271/06—Esters of carbamic acids
- C07C271/08—Esters of carbamic acids having oxygen atoms of carbamate groups bound to acyclic carbon atoms
- C07C271/10—Esters of carbamic acids having oxygen atoms of carbamate groups bound to acyclic carbon atoms with the nitrogen atoms of the carbamate groups bound to hydrogen atoms or to acyclic carbon atoms
- C07C271/22—Esters of carbamic acids having oxygen atoms of carbamate groups bound to acyclic carbon atoms with the nitrogen atoms of the carbamate groups bound to hydrogen atoms or to acyclic carbon atoms to carbon atoms of hydrocarbon radicals substituted by carboxyl groups
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
- C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
- C07F9/02—Phosphorus compounds
- C07F9/06—Phosphorus compounds without P—C bonds
- C07F9/22—Amides of acids of phosphorus
- C07F9/26—Amides of acids of phosphorus containing P-halide groups
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C2603/00—Systems containing at least three condensed rings
- C07C2603/02—Ortho- or ortho- and peri-condensed systems
- C07C2603/04—Ortho- or ortho- and peri-condensed systems containing three rings
- C07C2603/06—Ortho- or ortho- and peri-condensed systems containing three rings containing at least one ring with less than six ring members
- C07C2603/10—Ortho- or ortho- and peri-condensed systems containing three rings containing at least one ring with less than six ring members containing five-membered rings
- C07C2603/12—Ortho- or ortho- and peri-condensed systems containing three rings containing at least one ring with less than six ring members containing five-membered rings only one five-membered ring
- C07C2603/18—Fluorenes; Hydrogenated fluorenes
Definitions
- Nucleotide Probes PCT WO 8902439 assigned to Gen-Probe, Inc.
- those non-nucleotide reagents were of mixed chirality.
- Those reagents are coupled into the phosphodiester backbone of an oligonucleotide by chemical synthesis as disclosed therein.
- One aspect of the present invention provides nonnucleotide reagents which are suitable for preparing
- nucleotide/non-nucleotide polymer comprises at least one nucleotide monomeric unit.
- the ligand moiety may comprise a linker-arm group which may participate in conjugation reactions upon its activation or deprotection, a detectable chemical moiety or label or a side arm to which a detectable chemical moiety or label has been attached prior to initiating synthesis of the polymer.
- Suitable chemical moieties include detectable labels, chelators, catalysts, nucleolytic moieties, drug carriers, hormone receptors,
- Suitable chemical moieties include psoralen and analogs thereof, acridines and analogs thereof, porphyrins and porphyrin analogs, cyclic chelators and the like.
- deoxyribooligonucleotide is an oligonucleotide consisting of deoxyribonucleotide monomers.
- nucleotide multimer probe is a nucleotide multimer having a nucleotide sequence complementary with a target
- the probe usually is selected to be perfectly complementary to the corresponding base in the target sequence. However, in some cases it may be adequate or even desirable that one or more nucleotides in the probe not be complementary to the corresponding base in the target sequence.
- non-nucleotide monomeric unit refers to a monomeric unit which does not significantly participate in hybridization of a polymer. Such monomeric units must not, for example,
- nucleotide/non-nucleotide polymer refers to a polymer comprised of nucleotide and non-nucleotide monomeric units.
- oligonucleotide analogs such as phosphotriesters, and other oligonucleotide analogs and modified oligonucleotides, and also includes nucleotide/non-nucleotide polymers.
- the term also includes nucleotide/non-nucleotide polymers wherein one or more of the phosphorous group linkages between monomeric units has been replaced by a non-phosphorous group linkage such as a formacetal linkage or a carbamate linkage.
- alkyl- or aryl-phosphonate oligomer refers to nucleotide oligomers (or nucleotide/non-nucleotide polymers) having internucleoside (or intermonomer) phosphorus group linkages wherein at least one alkyl- or aryl- phosphonate linkage replaces a phosphodiester linkage.
- methylphosphonate oligomer refers to nucleotide oligomers (or nucleotide/non-nucleotide polymer) having internucleoside (or intermonomer) phosphorus group linkages wherein at least one methylphosphonate internucleoside linkage replaces a phosphate diester
- nucleoside includes a nucleosidyl unit and is used interchangeably therewith
- Figures 1A, 1B and 1C depict the formulas of non-nucleotide reagents of the present invention having Fmoc-procected linker arms.
- Figure 2 depicts a synthetic scheme for preparing non-nucleotide reagents of the present invention having C2, C4 and C6 linker arms.
- Figure 3 depicts a synthetic scheme for preparing non-nucleotide reagents of the present invention having C8 , C10 and C12 linker arms.
- Figure 4 depicts a synthetic scheme for a psoralen reagent which may form a psoralen conjugate with the- linker arm of one of the non-nucleotide reagents of the present invention.
- chemistries already known in the art include intercalators, alkylators, photoactivated reactive moieties such as psoralens, chelating agents, etc. We believe that by applying such chemistries, we will be able to increase the potency of methylphosphonate oligomers as
- the non-nucleotide based linking reagents are prepared in a chirally pure form. Moreover, these non-nucleotide reagents remain chirally pure when incorporated in oligomers (non-nucleotide/nucleotide polymers). This advantage may be critical when it is desired or desirable to direct a label to a particular location when the oligomer is hybridized to a corresponding carget nucleic acid.
- the hydrocarbon skeleton of these reagents comprises a reduction product of threonine. Since the four enantiomers of threonine are commercially available, non-nucleotide reagents having a chirally pure skeletons derived from any one of the four
- stereoisomers of threonine may be prepared.
- threonine as the starting material to supply the chirally pure skeleton for some of these reagents has additional advantages.
- non-nucleotide reagents in such a way that an alkyl- or aryl- phosphonate diester linkage results when these non-nucleotide reagents are inserted into the phosphorus backbone of the oligomer.
- Such reagents couple to nucleotides or other non-nucleotide reagents in high yield.
- these non-nucleotide reagents can be used for the attachment of psoralen analogs to the oligomers. These psoralen analogs are attached to a non-nucleotide reagent using a novel chemistry (See Example 13).
- the present invention provides a non-nucleotide reagent, with a non-nucleotide monomeric unit which can be coupled synthetically with specific nucleotide monomeric units from nucleotide reagents, to produce a defined sequence polymer which is comprised of nucleotide and non-nucleotide monomeric units.
- Said non-nucleotide reagent also possesses a ligand which may comprise a linker-arm moiety which may
- the techniques for linking moieties to the linker arm may be similar to the techniques for linking labels to groups on proteins. However, modifications of such techniques may be required.
- useful chemistries include the reaction of alkylamines with active esters, active imines, arylhalides, or isothiocyanates, and the reaction of tbiols with maleimides, haloacetyls, etc. (for further potential techniques see G.M. Means and R.E.
- Suitable protecting groups which can be used to protect the linker arm functional group during formation of a polymer are also similar to those used in protein chemistry (see for example, “The Peptides: Analysis and Synthesis, Biology,” Vol. 3, ed. E. Gross and J. Meienhofer, Academic Press, 1971). Due to the chemical nature of the non-nucleotide reagent, it may be placed at any desired position within the nucleotide monomer sequence. This makes it possible to design a wide variety of properties into polymers which contain nucleotide monomers. These include: (1) attachment of specific chemical moieties at any desired location within the polymer, such moieties can include (but are not limited to) detectable labels, intercalating agents,
- nucleolytic agents drugs, hormones, proteins, peptides, haptens, radical generators, nucleolytic agents, proteolytic agents, catalysts, receptor binding substances, and other binding substances of biological interest, and agents which modify DNA transport across a biological barrier (such as a membrane), and substances which alter solubility of a nucleotide multimer.
- a biological barrier such as a membrane
- nucleotide affinity supports it is possible to position such labels and intercalating agents adjacent to any desired nucleotide; (2) the ability to immobilize the defined sequence to a solid support employing its linker-arm for conjunction to a chemical moiety of said support in order to construct, for example, nucleotide affinity supports; (3) the ability to attach multiple chemical moieties to the polymer through linker-arms by incorporating multiple non-nucleotide monomeric units into the polymers; (4) the ability to construct polymers which differ from naturally occurring polynucleotides in that they have altered activities with proteins and enzymes which act on polynucleotides.
- non-nucleotide monomeric unit on the 3 ' terminus of an otherwise pure polynucleotide imparts resistance to degradation by snake venom phosphodiesterase.
- non-nucleotide monomeric units may create specific cleavage sites for other nucleases; (5) the ability to construct hybridization probes by interspersing hybridizable nucleotide and non-nucleotide monomeric units.
- a mixed block synthesis of nucleotide and non-nucleotide monomers can be produced, whereby a defined sequence of
- nucleotide monomers are synthesized followed by a stretch of the one or more non-nucleotide monomeric units followed by second block of defined sequence nucleotide monomers; (6) the ability to construct synthetic probes which simultaneously detect target nucleotide multimers which differ by one or more base pairs.
- labelled oligomers are constructed with a defined sequence comprised of nucleotide and non-nucleotide monomers.
- the non-nucleotide monomeric units are used to connect two or more defined sequence nucleotide
- non-nucleotide monomeric units are chemically labelled for use in cross-linking reactions.
- the non-nucleotide reagent is constructed in a manner to permit it to be added in a step-wise fashion to produce a mixed nucleotide/non-nucleotide polymer employing one of the current DNA synthesis methods.
- Such nucleotide and non-nucleotide reagents normally add in a step-wise fashion to attach their corresponding monomeric units to a growing oligomer chain which is covalently immobilized to a solid support.
- the first nucleotide is attached to the support through a cleavable ester linkage prior to the initiation of synthesis. Step-wise extension of the oligomer chain is normally carried out in the 3' to 5 ' direction.
- the present invention provides a non-nucleotide reagent for preparing polymers which contain a mixture of nucleotide and non-nucleotide monomeric units.
- Said non-nucleotide monomers additionally may contain one or more
- linker-arms or one or more linker-arms conjugated to a desired chemical moiety such as a label, a cross-linking agent or an intercalating agent.
- Such a non-nucleotide monomer additionally possesses two coupling groups so as to permit its step-wise inclusion into a polymer of nucleotide and non-nucleotide monomeric units.
- a first one of said coupling groups has the property that it can couple efficiently to the terminus of a growing chain of
- the second of said coupling groups is capable of further extending, in a step-wise fashion, the growing chain of mixed nucleotide and non-nucleotide monomers. This requires that the second coupling group be inactivated while the first coupling group is coupling, so as not to substantially couple at that time , but can thereafter be activated so as to then couple the non-nucleotide monomeric unit.
- the "inactivation” is preferably accomplished with a blocking group on the second coupling group, which can be removed to "activate" the second coupling group.
- inactivation and activation might be accomplished simply by changing reaction conditions (e.g., pH, temperature, altering the concentration of some other component in the reaction system) with second coupling groups of a suitable chemical structure, which also lend themselves to inactivation and activation by such techniques.
- Said coupling groups permit the adjacent attachment of either nucleotide or non-nucleotide monomeric units.
- said coupling groups operate through coupling and deblocking and deprotection steps which are compatible with one of the standard DNA synthesis methods.
- the non-nucleotide monomer preferably has a skeleton, to the ends of which the coupling groups are linked.
- the skeleton is preferably an acyclic one to twenty atom chain, and preferably an acylic hydrocarbon chain of from one to twenty carbon atoms. PREFERRED NON-NUCLEOTIDE REAGENTS
- Preferred non-nucleotide reagents comprise non- nucleotide monomeric units in which the skeleton has a backbone of up to about 10 carbon atoms in which said backbone comprises at least one asymmetric carbon which remains chirally pure upon being coupled into a nucleotide/non-nucleotide polymer.
- Skeletons having backbones of about three carbons are preferred, in part, because such backbones resemble the three-carbon spacing of deoxyribose groups.
- One preferred aspect of the present invention is directed to chirally pure non-nucleotide reagents which when incorporated in an oligomer comprise a chirally pure non- nucleotide monomeric unit of the formula:
- SKEL comprises a chirally pure non-nucleotide skeleton of from about 1 to about 20 carbon atoms, wherein -NHL, Y and Z are covalently linked to a carbon atom of SKEL, L is a ligand, Y is - CH 2 -, -O-, -S- or -NH- and Z is -O-, -S- or -NH-.
- SKEL further comprises a backbone of about 1 to about 10 carbon atoms separating Y and Z . Examples of non-nucleotide monomeric units incorporating these preferred SKEL groups include:
- X s groups are independently selected from hydrogen or alkyl and may be the same or different, and q and r are
- these preferred non-nucleotide reagents may be represented by the general formula:
- X is halogen or substituted amino
- X 2 is halogen, amino, or substituted amino, or O-
- R 5 is alkyl, optionally substituted alkoxy or optionally substituted aryloxy
- R 6 is alkyl, optionally substituted alkoxy or optionally substituted aryloxy, or if X 2 is O-, optionally hydrogen
- U is oxygen, sulfur or imino
- W is alkyl, aryl, alkoxy, aryloxy, alkylthio, arylthio, S-, O-, amino or substituted amino
- V is alkoxy, alkylthio, amino or substituted amino.
- non-nucleotide reagents which are capable of forming alkyl- or aryl-phosphonate, and in particular methylphosphonate, diester linkages between monomeric units, especially preferred non-nucleotide reagents include those wherein the first coupling group, -YCp 1 , is selected from
- X 1 is chloro or secondary amino and R 5 is alkyl; X 2 is substituted amino, halogen or O- and R 6 is alkyl.
- the ligand moiety, L is preferably selected from a functional moiety or from a protected linking arm which can be deprotected under non adverse conditions so as to capable of then linking with a functional moiety (under non-adverse
- L comprises a protecting group, Pr, or protected linker arm which can be deprotected under non-adverse conditions so as to be capable of then linking with a functional moiety, including a cross linking agent such as psoralen, or a drug carrier molecule.
- Preferred linker arms include those having one of the following formulas:
- n and m are independently integers between 1 and 15, preferably between 1 and 5, and Pr is a protecting group
- One group of particularly preferred non-nucleotide reagents has a skeleton derived from the amino acid threonine. These preferred reagents comprise a 3-carbon backbone having two asymmetric carbons, each of which remains chirally pure when incorporated in a nucleotide/non-nucleotide polymer.
- these reagents having threonine-derived backbones advantageously have a primary hydroxyl and a secondary hydroxyl, which due to their differing reactivities allow selectivity and high yields in the subsequent protection, deprotection, blocking, deblocking and derivatization steps.
- the first coupling group is associated with the secondary hydroxyl group and the second coupling group is associated with the primary hydroxyl.
- the threonine-based non-nucleotide is threonine-based non-nucleotide
- * C denotes an asymmetric carbon which is chirally pure, and wherein one of R 1 and R 2 is hydrogen and the other is -NH-L where L is a ligand moiety as hereinafter defined; one of R 3 and R 4 is hydrogen and the other is lower alkyl of about 1 to about 10 carbon atoms, -Y-Cp 1 is a first coupling group, and -ZCp 2 is a blocked second coupling group, wherein:
- X is halogen or substituted amino
- X 2 is halogen, amino, or substituted amino, or O-
- R 5 is alkyl, optionally substituted alkoxy or optionally substituted aryloxy
- R 6 is alkyl, optionally substituted alkoxy or optionally substituted aryloxy, or if X 2 is O-, optionally hydrogen
- U is oxygen or sulfur
- W is alkyl, aryl, alkoxy, alkylthio, aryloxy, arylthio, O-, S-, amino or substituted amino
- V is alkoxy, alkylthio, amino or substituted amino
- the ligand moiety, L is prererably selected from a functional moiety or from a protected linking arm which can be deprotected under non-adverse conditions so as to be capable of then linking with a functional moiety (under non-adverse conditions). Since non-nucleotide reagents which are capable of forming alkyl- or aryl-phosphonate, and in particular
- methylphosphonate, diester linkages between monomeric units are preferred especially preferred non-nucleotide reagents include those wherein the first coupling group, -YCp 1 , is selected from
- X is chloro or secondary amino and R 5 is alkyl; X 2 is substituted amino, halogen or O- and R 6 is alkyl.
- L comprises a protecting group, Pr, or a protected linker arm which can be deprotected under non-adverse conditions so as to be capable of then linking with a functional moiety, including a cross linking agent such as psoralen, or a drug carrier molecule.
- Preferred linker arms include those having one of the following formulas:
- n and m are independently integers between 1 and 15, preferably between 1 and 5, and Pr is a protecting group
- Suitable protecting groups, Pr include 9-fluorenylmethoxycarbonyl ("Fmoc”), trifluoroacetyl, phenoxyacetyl and the like. See, e.g., Chapter 7 of Greene, Theodore W. , "Protective Groups in Organic Synthesis", John Wiley & Son, New York, 1981. These linker arms may be conveniently prepared according to the reaction schemes outlined in Figures 2 and 3 and described the Examples herein.
- Fmoc 9-fluorenylmethoxycarbonyl
- Non-nucleotide reagents are useful in preparing oligomers haying ligand moieties conjugated to the oligomer without adversely affecting the nor-al base pairing associated with hybridization to a target nucleic acid.
- These ligand moieties may comprise functior al groups or protected linker arms which may later (after synthesis of the oligonucleotide) be deprotected and react with a labelling reagent to give a linker arm - labelling reagent complex.
- Functional groups of particular utility may include detectable labels, agents which react with a target nucleic acid such as cross-linking agents, agents which cleave the target nucleic acid, agents which increase the uptake of oligomers into cells or skin and agents which slow the excretion of oligomers from the body.
- a target nucleic acid such as cross-linking agents
- agents which cleave the target nucleic acid agents which increase the uptake of oligomers into cells or skin and agents which slow the excretion of oligomers from the body.
- non-nucleotide reagents are incoproated into oligomers having alkyl- or aryl- phosphonate linkages between monomeric units, it may be
- nucleotide monomeric units having modified ribosyl moieties advantageous to incorporate nucleotide monomeric units having modified ribosyl moieties.
- the incorporation of nucleotide units having 2'-o-alkyl-, in particular 2'-O-methyl, ribosyl moieties into alkyl- or aryl-phosphonate oligomers advantageously may improve hybridization of the oligomer to its complimentary target sequence.
- the reaction mixture was cooled to 5-10o C and quenched with dropwise addition of 0.25 M NaOH (100 ml).
- the mixture was evaporated to remove over 90% of THF and the residue was diluted with 100 ml of dimethylformamide which facilitates the filtration.
- the mixture was then filtered through a Whatman #1 paper using aspirator vacuum. The filtrate was evaporated to dryness and the residue was purified on a flash Silica Gel column. The column was packed with dichloromethane and the product was eluted with 50% methanol in dichloromethane.
- FMOC-GLYCYLAMIDO-CAPROIC ACID C8 .
- the desired non-nucleotide reagent (6 mmol) , which was made according to Examples 3 and 5 above, was dried by co- evaporation with dry pyridine and dissolved in 15 ml of dry pyridine. A solution of 2.2 g of dimethoxytrityl chloride in 20 ml of CH 2 Cl 2 /pyridine (1:1) was added dropwise with stirring.
- reaction continued at room temperature for 45 min. The progress of the reaction was monitored by TLC. After the completion of the reaction it was quenched by the addition of 2 ml methanol which was stirred for 10 min. The solvents were removed under reduced pressure and the residue was dissolved in 50 ml of dichloromethane and extracted with saturated sodium hydrogen carbonate (2 x 50 ml) followed by water (30 ml). The organic phase was dried (MgSOJ and filtered. After the
- a 4 mmol portion of a dimethoxytrityl (DMT) -blocked non-nucleotide reagent having a C6 linker arm was dried by co-evaporation with dry pyridine. The residue was dissolved in 20 ml of anhydrous dichloromethane. Under a closed argon
- a phosphate diester oligodeoxyribonucleotide was synthesized which incorporated a C8 methoxyphosphoramidite non-nucIeotide reagent in the following sequence:
- the C8 methoxyphosphoramidite non-nucleotide reagent (1-O-dimethcxytrityl-2-N[N'-(N"-fluorenyl-methoxycarbonyl-6-aminohexanoyl)-2-aminoacetyl]-3-O-[N,N-diisopropylmethoxy-phosphinyl]-2-amino-1,2-dihydroxybutane) was dissolved in dry acetonitrile at a concentration of 100 mM and coupled into the oligonucleotide sequence using a Biosearch Model 8750 DNA synthesizer by standard phosphoramidite chemistry (M.H.
- Methylphosphonate oligomers which incorporated non-nucleotide reagents of the present invention were synthesized using methylphosphonamidite monomers and non-nucleotide
- Non-nucleotide linker reagents were dissolved in acetonitrile at a concentration of 120 mM.
- DEBLOCK reagent 2.5% dichloroacetic acid in dichloromethane.
- OXIDIZER reagent 25 g/L iodine in 2.5% water, 25% 2,6-lutidine, 72.5% tetrahydrofuran.
- CAP A 10% acetic anhydride in acetonitrile.
- CAP B 0.625% N,N-dimethylaminopyridine in pyridine. The 5'-dimethoxytrityl protecting group was left on at the end of the synthesis to facilitate purification of the oligomers, as
- incorporating methylphosphonate oligomers were removed from the solid support by mixing with concentrated ammonium hydroxide for two hours at room temperature.
- the solution was drained from the support using an Econo-ColumnTM (Bio-Rad, Richmond, CA) and the support was ,washed five times with 1:1 acetonitrile/water.
- the eluted oligomer was then evaporated to dryness under vacuum at room temperature.
- the protecting groups were removed from the bases with a solution of ethylenediamine/ethanol/acetonitrile/water (50:23.5:23.5:2.5) for 6 hours at room temperature. The resulting solutions were then evaporated to dryness under vacuum.
- the phosphate diester oligonucleotide of Example 9 (19 nmoles) was suspended in 115 ⁇ l of 0.15 M HEPES buffer (pH 8.0).
- NHS-LC-biotin (Pierce Chemical Co., Rockford, IL) was added (10 ⁇ l of a 100 mM solution in dimethylsulfoxide). The solution was heated at 37oC for 30 minutes. Additional NHS-LC-biotin solution was added (10 ⁇ l) and the reaction was continued for 30 minutes at 37oC.
- the product was then dissolved in water (100 ⁇ l) and purified by reverse-phase HPLC chromatography according to the following method.
- the HPLC apparatus consisted of a Beckman System Gold Model 126 Solvent Module and Model 167 Detector interfaced to an IBM compatible computer.
- a PLRP-S column was used (Polymer Laboratories, 8 ⁇ , 300 A pore size, 4.6 mm i.d. x 250 mm long).
- Buffer B 50% acetonitrile in 50 mM triethylammonium acetate (pH 7) .
- a linear gradient of 20-60% B was run over 30 minutes at a flow rater of 1.5 ml/minute. Under these conditions, the biotinylated product oligonucleotide eluted at 10.3 minutes.
- the 32P-labelled biotinylated oligonucleotide (10,000 cpm) was dissolved in 0.5 ml of 50 mM sodium phosphate (pH 6.8), 0.5 M sodium chloride, 2 mM EDTA in a 1.5 ml microcentrifuge tube. Controls were also prepared containing the same components plus l mg/ml biotin (Calbiochem Corp., San Diego, CA) . Next, 50 -1 of steptavidin-agarose (Pierce Cher sal Co., Rockfo: IL) was added to each tube and the contents wt.re mixed on a vcrtexer for 15 minutes.
- LINKER NON-NUCLEOTIDE MONOMER WITH PSORALEN A C4 linker-modified methylphosphonate oligomer was prepared having the following sequence:
- HPLC purification of the solution of crude psoralenoligomer conjugate described above was conducted as follows: A Beckman System Gold analytical HPLC system was used with a
- Buffers used for elution were: Buffer A - 50 mM triethylammonium acetate (pH 7) ; Buffer B - 50% acetonitrile in 50 mM triethylammonium acetate (pH 7).
- the sample was loaded onto the column in five 100 ⁇ l portions at two minute intervals with a 500 ⁇ l sample loop while the column was flowing at 1.5 ml/min with 10% Buffer B. Next, a linear gradient from 10 - 70% Buffer B was run over 30 minutes. Fractions were collected at 0.5 minute intervals.
- the psoralen-modified methylphosphonate oligomer prepared according to the procedure of Example 13, was labeled at its 5'-end with 32P as described above (See Example 12).
- the resulting autoradiograph revealed upper bands for samples containing diester target oligonucleotide which migrated slower in the gel than the bands corresponding to psoralen-modified methylphosphonate oligomer alone.
- the bands were then excised from the wet gel with a scalpel and counted in a scintillation counter. Based on this method, it was determined that cross-linking of psoralen-modified methylphosphonate oligomer to its complementary diester target was greater than 95%.
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Biochemistry (AREA)
- Molecular Biology (AREA)
- General Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Biotechnology (AREA)
- Genetics & Genomics (AREA)
- Saccharide Compounds (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
Abstract
Priority Applications (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP92502337A JPH05507419A (ja) | 1990-08-09 | 1991-08-09 | オリゴマーのための改善された非ヌクレオチド系リンカー試薬 |
AU90710/91A AU664542B2 (en) | 1990-08-09 | 1991-08-09 | Improved non-nucleotide-based linker reagents for oligomers |
KR1019930700371A KR930701468A (ko) | 1990-08-09 | 1991-08-09 | 비-누클레오티드를 기초로 한 올리고머용 링커 시약 |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US56530790A | 1990-08-09 | 1990-08-09 | |
US565,307 | 1990-08-09 |
Publications (1)
Publication Number | Publication Date |
---|---|
WO1992002532A1 true WO1992002532A1 (fr) | 1992-02-20 |
Family
ID=24258038
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/US1991/008769 WO1992002532A1 (fr) | 1990-08-09 | 1991-08-09 | Reactifs de liaison ameliores a base de non nucleotide pour oligomeres |
Country Status (9)
Country | Link |
---|---|
EP (1) | EP0542928A4 (fr) |
JP (1) | JPH05507419A (fr) |
KR (1) | KR930701468A (fr) |
AU (1) | AU664542B2 (fr) |
CA (1) | CA2089087A1 (fr) |
IE (1) | IE912805A1 (fr) |
IL (1) | IL99068A (fr) |
NZ (1) | NZ239250A (fr) |
WO (1) | WO1992002532A1 (fr) |
Cited By (21)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP0542887A1 (fr) * | 1990-08-09 | 1993-05-26 | Genta Incorporated | Oligonucleotides de methylphosphonate conjugues avec du psoralene utilises en tant qu'agents therapeutiques contre la leucemie myelogene chronique |
WO1994012518A2 (fr) * | 1992-11-25 | 1994-06-09 | Gabor Igloi | Reactif pour le couplage de diverses substances a des acides nucleiques et procede pour sa preparation |
WO1994027615A1 (fr) * | 1993-05-26 | 1994-12-08 | Genta Incorporated | Conjugaisons oligomeres et leur utilisation |
WO1995013833A1 (fr) * | 1993-11-16 | 1995-05-26 | Genta Incorporated | Oligomeres synthetiques comprenant des liaisons phosphonate internucleosidyle de chiralite indefinie melangees avec des liaisons non phosphonate internucleosidyle |
WO1995014030A1 (fr) * | 1993-11-16 | 1995-05-26 | Genta Incorporated | Oligomeres synthetiques ayant des liaisons internucleosidyle phosphonate chiralement pures melangees avec des liaisons internucleosidyle non phosphonate |
WO1995018820A1 (fr) * | 1994-01-11 | 1995-07-13 | Isis Pharmaceuticals, Inc. | Diols monomeres et oligomeres a liaison phosphate formes a partir de ces derniers |
WO1996015105A1 (fr) * | 1994-11-15 | 1996-05-23 | Italfarmaco S.P.A. | Derives fluorenyl-hydroxamiques possedant une activite immunodepressive et anti-inflammatoire |
US5837856A (en) * | 1993-11-16 | 1998-11-17 | Genta, Incorporated | Chirally enriched synthetic phosphonate oligomers |
US5854410A (en) * | 1994-03-31 | 1998-12-29 | Genta Incorporated | Oligonucleoside cleavage compounds and therapies |
US5886177A (en) * | 1994-01-11 | 1999-03-23 | Isis Pharmaceuticals, Inc. | Phosphate linked oligomers |
US5955597A (en) * | 1993-11-16 | 1999-09-21 | Genta, Incorporated | Chirally enriched synthetic phosphate oligomers |
EP0959077A1 (fr) * | 1998-05-06 | 1999-11-24 | Tosoh Corporation | Sonde optiquement active d'ADN avec une liaison diester phosphonique |
US6008398A (en) * | 1995-01-18 | 1999-12-28 | Genzyme Corporation | Non-nucleotide phosphorus ester oligomers |
US6184389B1 (en) | 1994-01-11 | 2001-02-06 | Isis Pharmaceuticals, Inc. | Combinatorial libraries having aminodiol monomer subunits |
US6828427B1 (en) | 1994-01-11 | 2004-12-07 | Isis Pharmaceuticals, Inc. | Oligomeric aminodiol-containing compounds, libraries thereof, and process of preparing the same |
WO2011109398A2 (fr) | 2010-03-02 | 2011-09-09 | President And Fellows Of Harvard College | Procédés et compositions pour le traitement du syndrome d'angelman et des troubles du spectre autistique |
WO2012174446A1 (fr) | 2011-06-17 | 2012-12-20 | President And Fellows Of Harvard College | Frizzled 2 en tant que cible pour des anticorps thérapeutiques dans le traitement du cancer |
WO2013003112A1 (fr) | 2011-06-27 | 2013-01-03 | The Jackson Laboratory | Procédés et compositions pour le traitement du cancer et d'une maladie auto-immune |
US10450334B2 (en) | 2013-03-28 | 2019-10-22 | Japan Science And Technology Agency | Photoresponsive nucleotide analogue having photocrosslinking ability |
US11078211B2 (en) | 2017-07-26 | 2021-08-03 | Japan Advanced Institute Of Science And Technology | Photoresponsive nucleotide analog capable of photocrosslinking in visible light region |
US11214590B2 (en) | 2017-07-26 | 2022-01-04 | Japan Advanced Institute Of Science And Technology | Photoresponsive nucleotide analog capable of photocrosslinking in visible light region |
Families Citing this family (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20140178877A1 (en) * | 2012-12-20 | 2014-06-26 | Roche Molecular Systems, Inc. | Labeled Oligonucleotide Probes Used for Nucleic Acid Sequence Analysis |
Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US3440190A (en) * | 1965-09-08 | 1969-04-22 | Du Pont | Oligonucleotide compositions and the process for the preparation thereof |
WO1986000074A1 (fr) * | 1984-06-15 | 1986-01-03 | Institut National De La Sante Et De La Recherche M | Acides nucleiques marques chimiquement, leur utilisation et necessaire pour sa mise en oeuvre |
US4757141A (en) * | 1985-08-26 | 1988-07-12 | Applied Biosystems, Incorporated | Amino-derivatized phosphite and phosphate linking agents, phosphoramidite precursors, and useful conjugates thereof |
Family Cites Families (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
AU630076B2 (en) * | 1987-09-21 | 1992-10-22 | Gen-Probe Incorporated | Non-nucleotide linking reagents for nucleotide probes |
FR2642074B1 (fr) * | 1989-01-20 | 1994-04-29 | Oris Ind | Derives de molecules polyhydroxylees permettant l'introduction d'au moins une ramification dans un oligonucleotide |
-
1991
- 1991-08-02 IL IL99068A patent/IL99068A/en active IP Right Grant
- 1991-08-02 NZ NZ239250A patent/NZ239250A/xx unknown
- 1991-08-08 IE IE280591A patent/IE912805A1/en unknown
- 1991-08-09 AU AU90710/91A patent/AU664542B2/en not_active Ceased
- 1991-08-09 JP JP92502337A patent/JPH05507419A/ja active Pending
- 1991-08-09 EP EP19920900694 patent/EP0542928A4/en not_active Withdrawn
- 1991-08-09 WO PCT/US1991/008769 patent/WO1992002532A1/fr not_active Application Discontinuation
- 1991-08-09 KR KR1019930700371A patent/KR930701468A/ko not_active Application Discontinuation
- 1991-08-09 CA CA002089087A patent/CA2089087A1/fr not_active Abandoned
Patent Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US3440190A (en) * | 1965-09-08 | 1969-04-22 | Du Pont | Oligonucleotide compositions and the process for the preparation thereof |
WO1986000074A1 (fr) * | 1984-06-15 | 1986-01-03 | Institut National De La Sante Et De La Recherche M | Acides nucleiques marques chimiquement, leur utilisation et necessaire pour sa mise en oeuvre |
US4757141A (en) * | 1985-08-26 | 1988-07-12 | Applied Biosystems, Incorporated | Amino-derivatized phosphite and phosphate linking agents, phosphoramidite precursors, and useful conjugates thereof |
Non-Patent Citations (1)
Title |
---|
See also references of EP0542928A4 * |
Cited By (30)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP0542887A4 (en) * | 1990-08-09 | 1993-09-08 | Genta Incorporated | Psoralen conjugated methylphosphonate oligonucleotides as therapeutic agents for chronic myelogenous leukemia |
EP0542887A1 (fr) * | 1990-08-09 | 1993-05-26 | Genta Incorporated | Oligonucleotides de methylphosphonate conjugues avec du psoralene utilises en tant qu'agents therapeutiques contre la leucemie myelogene chronique |
WO1994012518A2 (fr) * | 1992-11-25 | 1994-06-09 | Gabor Igloi | Reactif pour le couplage de diverses substances a des acides nucleiques et procede pour sa preparation |
WO1994012518A3 (fr) * | 1992-11-25 | 1994-07-21 | Gabor Igloi | Reactif pour le couplage de diverses substances a des acides nucleiques et procede pour sa preparation |
WO1994027615A1 (fr) * | 1993-05-26 | 1994-12-08 | Genta Incorporated | Conjugaisons oligomeres et leur utilisation |
US5955597A (en) * | 1993-11-16 | 1999-09-21 | Genta, Incorporated | Chirally enriched synthetic phosphate oligomers |
WO1995013833A1 (fr) * | 1993-11-16 | 1995-05-26 | Genta Incorporated | Oligomeres synthetiques comprenant des liaisons phosphonate internucleosidyle de chiralite indefinie melangees avec des liaisons non phosphonate internucleosidyle |
WO1995014030A1 (fr) * | 1993-11-16 | 1995-05-26 | Genta Incorporated | Oligomeres synthetiques ayant des liaisons internucleosidyle phosphonate chiralement pures melangees avec des liaisons internucleosidyle non phosphonate |
US6028188A (en) * | 1993-11-16 | 2000-02-22 | Genta Incorporated | Synthetic oligomers having chirally pure phosphonate internucleosidyl linkages mixed with non-phosphonate internucleosidyl linkages |
US5792615A (en) * | 1993-11-16 | 1998-08-11 | Genta, Incorporated | Synthetic oligomers having chirally pure phoshonate internucleosidyl linkages mixed with non-phosphonate internucleosidyl linkages |
US5837856A (en) * | 1993-11-16 | 1998-11-17 | Genta, Incorporated | Chirally enriched synthetic phosphonate oligomers |
US5986083A (en) * | 1993-11-16 | 1999-11-16 | Genta, Inc. | Synthetic oligomers having phosphonate internucleosidyl linkages of undefined chirality mixed with non-phosphonate internucleosidyl linkages |
WO1995018820A1 (fr) * | 1994-01-11 | 1995-07-13 | Isis Pharmaceuticals, Inc. | Diols monomeres et oligomeres a liaison phosphate formes a partir de ces derniers |
US6448373B1 (en) | 1994-01-11 | 2002-09-10 | Isis Pharmaceuticals, Inc. | Phosphate linked oligomers formed of monomeric diols and processes for preparing same |
US6828427B1 (en) | 1994-01-11 | 2004-12-07 | Isis Pharmaceuticals, Inc. | Oligomeric aminodiol-containing compounds, libraries thereof, and process of preparing the same |
US6184389B1 (en) | 1994-01-11 | 2001-02-06 | Isis Pharmaceuticals, Inc. | Combinatorial libraries having aminodiol monomer subunits |
US5886177A (en) * | 1994-01-11 | 1999-03-23 | Isis Pharmaceuticals, Inc. | Phosphate linked oligomers |
US5854410A (en) * | 1994-03-31 | 1998-12-29 | Genta Incorporated | Oligonucleoside cleavage compounds and therapies |
WO1996015105A1 (fr) * | 1994-11-15 | 1996-05-23 | Italfarmaco S.P.A. | Derives fluorenyl-hydroxamiques possedant une activite immunodepressive et anti-inflammatoire |
US6008398A (en) * | 1995-01-18 | 1999-12-28 | Genzyme Corporation | Non-nucleotide phosphorus ester oligomers |
EP1340766A1 (fr) * | 1998-05-06 | 2003-09-03 | Tosoh Corporation | Sonde optiquement active d'ADN avec une liaison diester phosphonique |
US6211354B1 (en) | 1998-05-06 | 2001-04-03 | Tosch Corporation | Optically active DNA probe having phosphonic diester linkage |
EP0959077A1 (fr) * | 1998-05-06 | 1999-11-24 | Tosoh Corporation | Sonde optiquement active d'ADN avec une liaison diester phosphonique |
WO2011109398A2 (fr) | 2010-03-02 | 2011-09-09 | President And Fellows Of Harvard College | Procédés et compositions pour le traitement du syndrome d'angelman et des troubles du spectre autistique |
WO2012174446A1 (fr) | 2011-06-17 | 2012-12-20 | President And Fellows Of Harvard College | Frizzled 2 en tant que cible pour des anticorps thérapeutiques dans le traitement du cancer |
EP3281640A1 (fr) | 2011-06-17 | 2018-02-14 | President and Fellows of Harvard College | Frizzled 2 en tant que cible pour des anticorps thérapeutiques dans le traitement du cancer |
WO2013003112A1 (fr) | 2011-06-27 | 2013-01-03 | The Jackson Laboratory | Procédés et compositions pour le traitement du cancer et d'une maladie auto-immune |
US10450334B2 (en) | 2013-03-28 | 2019-10-22 | Japan Science And Technology Agency | Photoresponsive nucleotide analogue having photocrosslinking ability |
US11078211B2 (en) | 2017-07-26 | 2021-08-03 | Japan Advanced Institute Of Science And Technology | Photoresponsive nucleotide analog capable of photocrosslinking in visible light region |
US11214590B2 (en) | 2017-07-26 | 2022-01-04 | Japan Advanced Institute Of Science And Technology | Photoresponsive nucleotide analog capable of photocrosslinking in visible light region |
Also Published As
Publication number | Publication date |
---|---|
IL99068A (en) | 1998-01-04 |
CA2089087A1 (fr) | 1992-02-10 |
JPH05507419A (ja) | 1993-10-28 |
EP0542928A1 (fr) | 1993-05-26 |
AU9071091A (en) | 1992-03-02 |
IL99068A0 (en) | 1992-07-15 |
NZ239250A (en) | 1993-12-23 |
AU664542B2 (en) | 1995-11-23 |
EP0542928A4 (en) | 1994-07-27 |
IE912805A1 (en) | 1992-02-12 |
KR930701468A (ko) | 1993-06-11 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
AU664542B2 (en) | Improved non-nucleotide-based linker reagents for oligomers | |
US6846922B1 (en) | Activators for oligonucleotide synthesis | |
Gamper et al. | Facile preparation of nuclease resistant 3′ modified oligodeoxynucleotides | |
US6335434B1 (en) | Nucleosidic and non-nucleosidic folate conjugates | |
US6528631B1 (en) | Oligonucleotide-folate conjugates | |
US5916750A (en) | Multifunctional linking reagents for synthesis of branched oligomers | |
EP0592434B1 (fr) | Procede ameliore de synthese d'oligomeres | |
FI117135B (fi) | Polyamidi-oligonukleotidijohdoksia, niiden valmistus ja niiden käyttö | |
JPH02503146A (ja) | ヌクレオチドプローブ用非ヌクレオチド連結試薬 | |
WO1995023162A1 (fr) | Duplex d'oligonucleotides modifies a activite anticancereuse | |
FR2607507A1 (fr) | Nouveaux derives a-d-oligonucleotides, leur preparation et leur emploi | |
EP0542887B1 (fr) | Oligonucleotides de methylphosphonate conjugues avec du psoralene utilises en tant qu'agents therapeutiques contre la leucemie myelogene chronique | |
WO1997029116A1 (fr) | Phosphoramidites de dinucleotides contenant du soufre | |
CA2406168C (fr) | Derives du pna (polyamide nucleic acid), agents et methodes permettant de les produire | |
US6300486B1 (en) | Large scale synthesis of oligonucleotides and their associated analogs | |
Acedo et al. | Preparation of oligonucleotide-dexamethasone conjugates | |
ES2256729T3 (es) | Metalocenos bifuncionalizados, utilizacion para el marcaje de moleculas biologicas. | |
JAWORSKA-MASLANKA et al. | Studies on stereospecific formation of P-chiral internucleotide linkage: synthesis of all-Rp and all-Sp methylphosphonate pentanucleotide d (MMTrAPMeTPMeTPMeCPMeTAc) via Grignard activated coupling | |
Goula | Synthesis of novel lipophilic nucleotide and CpG dinucleotide conjugates for the stimulation of the immune response system |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
AK | Designated states |
Kind code of ref document: A1 Designated state(s): AU CA FI JP KR NO SU |
|
AL | Designated countries for regional patents |
Kind code of ref document: A1 Designated state(s): AT BE CH DE DK ES FR GB GR IT LU NL SE |
|
COP | Corrected version of pamphlet |
Free format text: PAGES 1-35,DESCRIPTION,REPLACED BY NEW PAGES 1-34;PAGES 36-48,CLAIMS,REPLACED BY NEW PAGES 35-48;PAGES 1/4-4/4,DRAWINGS,REPLACED BY NEW PAGES 1/7-7/7;DUE TO LATE TRANSMITTAL BY THE RECEIVING OFFICE |
|
CFP | Corrected version of a pamphlet front page | ||
CR1 | Correction of entry in section i |
Free format text: IN PAT.BUL.05/92,UNDER INID (22) "INTERNATIONAL FILING DATE" REPLACE "910812)" BY "910809" |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2089087 Country of ref document: CA |
|
WWE | Wipo information: entry into national phase |
Ref document number: 1992900694 Country of ref document: EP |
|
WWP | Wipo information: published in national office |
Ref document number: 1992900694 Country of ref document: EP |
|
WWW | Wipo information: withdrawn in national office |
Ref document number: 1992900694 Country of ref document: EP |